Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease

被引：0
|
作者：
Robert Deicher
Walter H. Hörl
机构：
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] Universitätsklinik für Innere Medizin III,Klinische Abteilung für Nephrologie und Dialyse
来源：
Drugs | 2004年 / 64卷
关键词：
Chronic Kidney Disease; Subcutaneous Administration; Peritoneal Dialysis Patient; Sialic Acid Residue; Erythropoiesis Stimulate Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endogenous erythropoietin (EPO) consists of a central polypeptide core covered by post-translationally linked carbohydrates. Three of the four currently available erythropoiesis stimulating agents (ESA) — epoetin-α, epoetin-β and epoetin-ω — are composed of an identical amino acid sequence, but glycosylation varies as a result of type- and host cell-specific differences in the production process.
引用
收藏
页码：499 / 509
页数：10
相关论文
共 50 条
  • [41] Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease
    Keithi-Reddy, Sai Ram
    Addabbo, Francesco
    Patel, Tejas V.
    Mittal, Bharati V.
    Goligorsky, Michael S.
    Singh, Ajay K.
    KIDNEY INTERNATIONAL, 2008, 74 (06) : 782 - 790
  • [42] Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis
    Jose Perez-Ruixo, Juan
    Cucala-Ramos, Mercedes
    Garcia-Gonzalo, Ester
    Del Val Romero, Beatriz
    Valveny, Neus
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 15 - 25
  • [43] Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations
    Abraham, Ivo
    MacDonald, Karen
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (06) : 885 - 887
  • [44] Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial
    Fliser, Danilo
    Dellanna, Frank
    Koch, Michael
    Wiggenhauser, Alfons
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (02) : 279 - 287
  • [45] Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?
    Di Lullo, Luca
    Floccari, Fulvio
    Granata, Antonio
    Malaguti, Moreno
    CARDIORENAL MEDICINE, 2012, 2 (01) : 18 - 25
  • [46] Role of parathyroidectomy on anemia control and erythropoiesis-stimulating agent need in secondary hyperparathyroidism of chronic kidney disease. A retrospective study in 30 hemodialysis patients
    Conzo, Giovanni
    Perna, Alessandra
    Della Pietra, Cristina
    Esposito, Daniela
    Nunziata, Anna
    Palazzo, Antonietta
    Pizza, Alessandra
    Satta, Ersilia
    Sciascia, Valerio
    Santini, Luigi
    ANNALI ITALIANI DI CHIRURGIA, 2013, 84 (01) : 25 - 31
  • [47] Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis
    Kuo, Ko-Lin
    Hung, Szu-Chun
    Liu, Jia-Sin
    Chang, Yu-Kang
    Hsu, Chih-Cheng
    Tarng, Der-Cherng
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (09) : 1518 - 1525
  • [48] A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents
    Nangaku, Masaomi
    Kondo, Kazuoki
    Takabe, Souichirou
    Ueta, Kiichiro
    Tandai, Tsubasa
    Kawaguchi, Yutaka
    Komatsu, Yasuhiro
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (01) : 45 - 54
  • [49] Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents
    Brenner, Nicole
    Kommalapati, Anuhya
    Ahsan, Muhammad
    Ganguli, Anirban
    JOURNAL OF NEPHROLOGY, 2020, 33 (02) : 267 - 275
  • [50] Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents
    Nicole Brenner
    Anuhya Kommalapati
    Muhammad Ahsan
    Anirban Ganguli
    Journal of Nephrology, 2020, 33 : 267 - 275
12345